No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Haohai Biotech (06826.HK) plans to hold a board of directors meeting on August 16 to approve its mid-term performance.
Haohai Biotech (06826.HK) announced that the board of directors is scheduled to hold a meeting on Friday, August 16, 2024, to review and approve the company's and its subsidiaries' mid-year performance ending on June 30, 2024, and its release, as well as to consider recommending the distribution of interim dividends (if any).
HAOHAI BIOTEC: DATE OF BOARD MEETING
Haohai Biotec (06826.HK): In July, it accumulated repurchased 0.2652 million A-shares through centralized bidding trading.
On July 2024, haohai biotec (06826.HK) announced that the company has accumulated the repurchase of 0.2652 million A-shares of the company through centralized competitive bidding, accounting for 0.11% of the total share capital at the highest fill price of HKD 62.90 per share and the lowest fill price of HKD 58.45 per share. The total transaction amount is RMB 16.1091 million (excluding stamp duty, transaction commission and other transaction costs). As of July 31, 2024, the company has accumulated the repurchase of 2.0157 million A-shares through centralized competitive bidding.
Shanghai Haohai Biological Technology (688366.SH): Has cumulatively repurchased 0.86% of the company's A-share stocks.
On August 1st, Gelunhui reported that Shanghai Haohai Biological Technology (688366.SH) has repurchased 2,015,674 shares of A shares through centralized bidding trading as of July 31, 2024, accounting for 0.86% of the total share capital of 235,489,895 shares (the total share capital of A shares and H shares in this announcement was calculated after the completion of the transfer of capital reserve to share capital of A shares and H shares in June and July 2024, respectively), the highest fill price was 113.50 yuan/share, and the lowest fill price was 58.4.
Shareholder Lou Guoliang of Haohai Biotec plans to reduce his shareholding by no more than 0.6 million shares.
Haohai Biotec (06826) announced that Mr. Lou Guoliang holds 8.6117 million shares of Shanghai Haohai Biotec Co., Ltd. (hereinafter referred to as the "company"), accounting for 3.66% of the total share capital of 0.235 billion shares as of the disclosure date of this announcement. The above-mentioned shares are obtained from the shares before the company's initial public offering and the shares obtained through the capital reserve fund. Among them, the shares before the initial public offering have been released from restrictions and listed for circulation on October 30, 2020, and the shares obtained through the capital reserve fund will be listed for circulation on June 20, 2024. Mr. Lou Guoliang holds the shares for his own benefit.
No Data